HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease [EXTENSION OF 700046174]

Trial Profile

HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease [EXTENSION OF 700046174]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Latrepirdine (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions
  • Acronyms HORIZON-PLUS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top